The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Vistagen Therapeutics 9-Day RSI Related Terms
MEX:VTGN vs PSTV, KYNB, TVGN: 9-Day RSI Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (MEX:VTGN) has a 9-Day RSI of 68.80 as of Jul. 07, 2026. According to the industry distribution chart, Vistagen Therapeutics ranks #63 out of 1417 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Vistagen Therapeutics' 9-Day RSI too high?
Vistagen Therapeutics' current 9-Day RSI is 68.80. The Biotechnology industry median 9-Day RSI is 53.73. Vistagen Therapeutics' value of 68.80 is 28% above this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #63 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' 9-Day RSI compare to PSTV and KYNB?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #63 out of 1417 companies for 9-Day RSI. This places Vistagen Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.73. Vistagen Therapeutics' value of 68.80 is 28% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current 9-Day RSI of 68.80 is 28% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current 9-Day RSI is 68.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current 9-Day RSI of 68.80. The stock's GF Value™ is MXN95.99, compared to a current price of MXN10.65 — trading 88.9% below its estimated fair value. The current 9-Day RSI is 68.80 and 28% above the Biotechnology industry median of 53.73. Vistagen Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current 9-Day RSI is 68.80 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of MXN10.65 is trading 88.9% below its estimated GF Value™ of MXN95.99.
Key valuation signals for MEX:VTGN:
9-Day RSI: 68.80
GF Value™: MXN95.99 vs. price of MXN10.65 (88.9% below fair value)
Industry Position: 28% above the Biotechnology median (#63 of 1417)
No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score
Get the complete analysis for MEX:VTGN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VTGN has been successfully added to your 